Quick Answer
Tarsus Pharmaceuticals, Inc. reported Long-Term Debt of $72.44 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $72.44M | +0.8% |
| 2024 | $71.84M | +140.9% |
| 2023 | $29.82M | +53.4% |
| 2022 | $19.43M | — |
| 2021 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $72.28M | +0.8% | +0.2% |
| June 30, 2025 | $72.13M | +0.8% | +0.2% |
| March 31, 2025 | $71.98M | +140.5% | +0.2% |
| December 31, 2024 | $71.84M | +140.9% | +0.2% |
| September 30, 2024 | $71.71M | +141.4% | +0.2% |
| June 30, 2024 | $71.58M | +190.9% | +139.1% |
| March 31, 2024 | $29.93M | +22.1% | +0.4% |
| December 31, 2023 | $29.82M | +53.4% | +0.4% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +0.8% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: